RAPP official logo RAPP
RAPP 1-star rating from Upturn Advisory
Rapport Therapeutics, Inc. Common Stock (RAPP) company logo

Rapport Therapeutics, Inc. Common Stock (RAPP)

Rapport Therapeutics, Inc. Common Stock (RAPP) 1-star rating from Upturn Advisory
$24.92
Last Close (24-hour delay)
Profit since last BUY48.33%
upturn advisory logo
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

11/10/2025: RAPP (1-star) is a SELL. SELL since 1 days. Simulated Profits (48.33%). Updated daily EoD!

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

2 star rating from financial analysts

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $52.14

1 Year Target Price $52.14

Analysts Price Target For last 52 week
$52.14 Target price
52w Low $6.43
Current$24.92
52w High $42.27

Analysis of Past Performance

Type Stock
Historic Profit -8.19%
Avg. Invested days 28
Today’s Advisory SELL
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.22B USD
Price to earnings Ratio -
1Y Target Price 52.14
Price to earnings Ratio -
1Y Target Price 52.14
Volume (30-day avg) 5
Beta -
52 Weeks Range 6.43 - 42.27
Updated Date 11/10/2025
52 Weeks Range 6.43 - 42.27
Updated Date 11/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.27

Earnings Date

Report Date 2025-11-06
When -
Estimate -0.732
Actual -0.71

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -15.89%
Return on Equity (TTM) -23.41%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1067489724
Price to Sales(TTM) -
Enterprise Value 1067489724
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 47661138
Shares Floating 30079897
Shares Outstanding 47661138
Shares Floating 30079897
Percent Insiders 4.71
Percent Institutions 90.12

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock(RAPP) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Rapport Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for central nervous system (CNS) disorders. Founded in 2022, Rapport is working to advance precision therapeutics by leveraging the insights gained from the identification and understanding of genetic drivers of neurological disorders. They target specific receptor-associated proteins.

Company business area logo Core Business Areas

  • Discovery and Development of CNS Therapeutics: Rapport Therapeutics focuses on the discovery and development of precision medicines targeting genetically defined neurological conditions. Their strategy involves identifying and validating receptor-associated proteins as drug targets.
  • Preclinical and Clinical Programs: Rapport Therapeutics is working to build a robust pipeline of preclinical and clinical programs focused on addressing unmet needs in neurological disorders. Their lead programs target specific receptor associated proteins with the goal of improved efficacy and reduced side effects compared to current treatments.

leadership logo Leadership and Structure

Rapport Therapeutics has a management team with experience in drug discovery and development. The organizational structure appears to be based around research and development, clinical trials, and business development.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • RAP-219: RAP-219 is Rapport Therapeutics' lead clinical program, targeting pain. It is a selective and potent inhibitor designed to modulate the activity of genetically validated pain targets. As a Phase 1 trial is underway, there is no current revenue, market share, or number of users. Competitors: Existing pain medications (opioids, NSAIDs, etc.) and other companies developing novel pain therapies.

Market Dynamics

industry overview logo Industry Overview

The CNS therapeutics market is large and growing, with significant unmet needs in many neurological disorders. Factors driving growth include an aging population, increasing prevalence of neurological conditions, and advances in drug discovery and development.

Positioning

Rapport Therapeutics positions itself as a leader in precision CNS therapeutics, leveraging genetics to develop targeted therapies. Its competitive advantage lies in its focus on genetically defined patient populations and its ability to design drugs that selectively modulate the activity of disease-causing proteins.

Total Addressable Market (TAM)

The TAM for CNS therapeutics is estimated to be significant, potentially in the hundreds of billions of dollars. Rapport Therapeutics is positioned to capture a share of this market by focusing on specific, genetically defined patient populations with high unmet needs.

Upturn SWOT Analysis

Strengths

  • Strong scientific team
  • Focus on precision medicine
  • Novel drug targets
  • Proprietary technology platform

Weaknesses

  • Early stage company
  • Limited clinical data
  • Dependence on key personnel
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline into new indications
  • Advancement of clinical programs
  • Regulatory approvals

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

Key competitor logo Key Competitors

  • BIOX
  • ALNY
  • VIR

Competitive Landscape

Rapport Therapeutics competes with other biotechnology companies developing CNS therapeutics. Its focus on precision medicine and genetically defined patient populations could provide a competitive advantage.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company's recent founding. Growth is focused on advancing preclinical and clinical programs.

Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of its products. Analyst estimates are unavailable due to limited coverage.

Recent Initiatives: Recent initiatives include advancing the RAP-219 clinical program and expanding the pipeline through drug discovery efforts.

Summary

Rapport Therapeutics is an early-stage biotech company focused on precision CNS therapies, offering both potential and risk. Its strategic focus and strong scientific team represent key strengths, however its reliance on financing and clinical trial success pose significant challenges. The company needs to successfully advance its clinical programs and secure additional funding, and they must be aware of the competitive landscape.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Press Releases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made with careful consideration of all available information and risk factors.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Rapport Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2024-06-07
CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 69
Full time employees 69

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.